ZNTL
Zentalis Pharmaceuticals Llc
NASDAQ: ZNTL · HEALTHCARE · BIOTECHNOLOGY
$4.01
+1.26% today
Updated 2026-04-30
Market cap
$287.27M
P/E ratio
—
P/S ratio
7.13x
EPS (TTM)
$-1.91
Dividend yield
—
52W range
$1 – $7
Volume
2.2M
Zentalis Pharmaceuticals Llc (ZNTL) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14000.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $67.42M | $0.00 |
| Revenue growth (YoY) | — | -100.0% | — | — | — | — | — | -100.0% |
| Cost of revenue | — | $111000.00 | $160000.00 | $544000.00 | $1.43M | $1.39M | $1.29M | $739000.00 |
| Gross profit | $14000.00 | $-111000.00 | $-160000.00 | $-544000.00 | $-1.43M | $-1.39M | $67.42M | $-739000.00 |
| Gross margin | 100.0% | — | — | — | — | — | 100.0% | — |
| R&D | $18.92M | $38.39M | $84.90M | $175.60M | $172.73M | $235.16M | $167.77M | $107.30M |
| SG&A | $4.88M | $8.46M | $33.89M | $40.94M | $54.55M | $59.40M | $87.11M | $37.72M |
| Operating income | $-23.78M | $-46.84M | $-118.79M | $-216.54M | $-227.29M | $-299.51M | $-191.19M | $-146.25M |
| Operating margin | -169878.6% | — | — | — | — | — | -283.6% | — |
| EBITDA | $-23.73M | $-46.73M | $-118.63M | $-207.20M | $-225.86M | $-247.60M | $-186.17M | $-145.51M |
| EBITDA margin | -169514.3% | — | — | — | — | — | -276.1% | — |
| EBIT | $-23.78M | $-46.84M | $-118.79M | $-207.74M | $-227.29M | $-248.99M | $-187.46M | $-146.25M |
| Interest expense | $0.00 | $1.20M | $2.23M | $110.05M | $2.58M | — | — | — |
| Income tax | $4000.00 | $15000.00 | $444000.00 | $-297000.00 | $-469000.00 | $-601000.00 | $177000.00 | — |
| Effective tax rate | -0.0% | -0.0% | -0.4% | 0.2% | 0.2% | 0.2% | -0.1% | 0.0% |
| Net income | $-21.07M | $-45.66M | $-117.84M | $-158.72M | $-236.81M | $-292.19M | $-165.84M | $-137.06M |
| Net income growth (YoY) | — | -116.8% | -158.1% | -34.7% | -49.2% | -23.4% | +43.2% | +17.4% |
| Profit margin | -150478.6% | — | — | — | — | — | -246.0% | — |